TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04351048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stepwise Excavation
Description: * stepwise excavation includes selective caries removal to soft dentine on pulpal wall in the first stage of the excavation and~* after six months, the second stage of intervention includes re-entring the cavities and wall selective removal to firm dentine on pulpal wall.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Step Excavation
Description: \*one step excavations is completed in the first stage via performing selective removal to soft dentine on pulpal wall of the cavities.
Study: NCT00416702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAB149
Study: NCT05027243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral temporomandibular joint arthroscopy
Description: The TMJ arthroscopy was performed with a 1.9-mm arthroscope including a video system, with a 2.8-mm outer protective cannula. Briefly, for TMJ arthroscopy level 1, the authors used the classic puncture with an entry point 10 mm anterior and 2 mm below the Holmlund-Hellsing (H-H) line. A second puncture with a 21-G needle was performed 30 mm anterior and 7 mm below the H-H line to wash the joint with 250-300 ml Ringer solution. After washing the joint, 1.5-2 cc of hyaluronic acid was injected into it. For level 2 TMJ arthroscopy, the second puncture was substituted by a 2.8-mm outer protective cannula with a sharp trocar until the joint was reached. The 2.8-mm cannula was used for (1) intra-articular coblation and/or (2) intrasynovial medication. Antibiotic and non-steroidal anti-inflammatory drugs were routinely prescribed. Patients were instructed to follow a soft diet for 3 days after surgery and 5 physiotherapy and 3 speech therapy exercise sessions after intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeomin® (Merz)
Description: For tenderness grade 2, 155U of Incobotulinum toxin A was injected in the masticatory muscles and for tenderness grade 3 195U of Incobotulinum toxin A was injected. The authors used Xeomin® (Merz) in all patients.
Study: NCT03893435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
Study: NCT03295604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCTG+EMD
Description: Miller class I-II gingival recession defects were operated with SCTG+EMD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCTG
Description: Miller class I-II gingival recession defects were operated with SCTG only and
Study: NCT00442260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Study: NCT03138525

Intervention type: OTHER
Intervention: Blood sampling (controls)
Description: Blood samples will be collected once at enrollment.
Study: NCT03742570

Intervention type: BEHAVIORAL
Intervention: CBBDQ
Description: a questionnaire for childood bladder and bowel dysfunctions
Study: NCT02795754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 PIB
Description: GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 PIB
Description: GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 PIB
Description: GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 IR1
Description: GSK2838232 will be available as film-coated tablet for oral use
Study: NCT04625426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Cavilon No-Rinse Skin Cleanser and 3M Cavilon Advanced Skin Protectant
Description: Hypoallergenic no-rinse skin cleanser and liquid acrylic tetrapolymer skin protectant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conveen EasiCleanse and Conveen Critic Barrier
Description: Hypoallergenic no-rinse skin cleanser and zinc-oxide barrier cream
Study: NCT02795754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232 IR2
Description: GSK2838232 will be available as film-coated tablet for oral use
Study: NCT04625426

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cleansing and Conveen Critic Barrier
Description: Hospital's standard care for IAD management
Study: NCT02795754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo PIB
Description: Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo PIB
Description: Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
Study: NCT01184326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study: NCT01615393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: Single oral dose of 400 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin [Vilona]
Description: Single oral dose of a 400 mg capsule
Study: NCT01131780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen + Pseudoephedrine Hydrochloride
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Pseudoephedrine Hydrochloride
Description: Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
Study: NCT02343913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAC checklist
Study: NCT02171819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVACFLU-A/H5N1, 7.5 mcg
Description: Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVACFLU-A/H5N1, 15 mcg
Description: Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: PBS, pH 7.2 in 0.5 mL single-dose vials.
Study: NCT03684941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Period One
Description: LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
Study: NCT03465813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaringGuidance After Breast Cancer Diagnosis
Description: CaringGuidance After Breast Cancer Diagnosis, psychoeducational, Internet-accessible program
Study: NCT03849352

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle changes with the support of health technology
Description: Written instructions will be provided to participants, to include how to download supportive apps on smartphones. Participants will be asked to complete a 3 day food diary using an online platform (MyFood24) prior to attending a face to face consultation which will reinforce the participant's responsibilities. Participants will be assisted to set specific diet and lifestyle goals. 3 fortnightly follow ups will be arranged via 15 minute telephone consultations, three 24 hour dietary diaries will be completed via MyFood24 prior to each fortnightly digital consultation. Participants will be asked to measure their daily activity via a pedometer on their smart phones. Participants will be asked to complete the Godin leisure time questionnaire to assess changes in leisure time exercise.
Study: NCT03390296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-OX40 Agonist Monoclonal Antibody PF-04518600
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-OX40 Agonist Monoclonal Antibody PF-04518600
Description: Given IV
Study: NCT03684941

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment Period Two
Description: CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
Study: NCT01150760

Intervention type: DRUG
Intervention: Alvimopan
Description: At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
Study: NCT00953004

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fiber drink and fiber bread
Description: fiber drink or fiber bread three times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fiber drink and fiber bread
Description: fiber drink or fiber bread three times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fiber drink and fiber bread
Description: fiber drink or fiber bread three times daily
Study: NCT04514588

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: caffeine consumption
Description: In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: caffeine consumption
Description: In this trial we are going to study the results of the consumption of 5mgr/kgr body weight of caffeine on appetite, food consumption and hormones ghrelin, asprosin, leptin and pancreatic polypeptide in relation to gene polymorphisms that affect caffeine metabolism and body weight
Study: NCT02428673

Intervention type: OTHER
Group type: OTHER
Intervention: Assisted Standing Treatment Program
Study: NCT04569799

Intervention type: DRUG
Group type: OTHER
Intervention: Lumason
Description: 2.4 mL per lesion
Study: NCT00756704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation guideline implementation
Description: 1. a tutorial on brief cessation counseling for ED nurses and physicians~2. use of an ED algorithm that includes recommended tobacco counseling items~3. fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~4. group feedback to ED staff
Study: NCT01851863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupentixol-Melitracen(psychological and GI) + Omeprazole
Description: Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupentixol-Melitracen(psychological) + Omeprazole
Description: Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupentixol-Melitracen(without explanation) + Omeprazole
Description: Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
Study: NCT02657876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExpressGraft-C9T1 Skin Tissue
Description: ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
Study: NCT01864317

Intervention type: DEVICE
Group type: OTHER
Intervention: 7-Tesla MRI
Description: High resolution functional and structural imaging of the visual pathway

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-Tesla MRI
Description: High resolution functional and structural imaging of the visual pathway

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-Tesla MRI
Description: High resolution functional and structural imaging of the visual pathway

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7-Tesla MRI
Description: High resolution functional and structural imaging of the visual pathway

Intervention type: OTHER
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: Measurement of retinal nerve fiber thickness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Measurement of retinal nerve fiber thickness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Measurement of retinal nerve fiber thickness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Measurement of retinal nerve fiber thickness

Intervention type: OTHER
Group type: OTHER
Intervention: Heidelberg Retina Tomography
Description: Measurement of retinal nerve fiber thickness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomography
Description: Measurement of retinal nerve fiber thickness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomography
Description: Measurement of retinal nerve fiber thickness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomography
Description: Measurement of retinal nerve fiber thickness
Study: NCT01822275

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy with Temodar.
Description: Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation therapy
Study: NCT02365870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rotigotine transdermal patch
Description: Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
Study: NCT01864317

Intervention type: OTHER
Group type: OTHER
Intervention: Scanning Laser Polarimetry
Description: Measurement of retinal nerve fiber thickness
Study: NCT02365870

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive a placebo transdermal patch to be worn daily
Study: NCT01957072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention
Description: The behaviour change intervention consists of~1. feedback via a web-based food diary~2. 'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behaviour change intervention
Description: The behaviour change intervention consists of~1. feedback via a web-based food diary~2. 'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails.
Study: NCT01254266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient hospitalization and follow up
Description: An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient treatment and follow up
Description: one month inpatient treatment followed by a year-long follow up on the inpatient unit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: bariatric surgery.
Study: NCT01864317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scanning Laser Polarimetry
Description: Measurement of retinal nerve fiber thickness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scanning Laser Polarimetry
Description: Measurement of retinal nerve fiber thickness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scanning Laser Polarimetry
Description: Measurement of retinal nerve fiber thickness

Intervention type: OTHER
Group type: OTHER
Intervention: Humphrey Perimetry
Description: Visual Field Testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Humphrey Perimetry
Description: Visual Field Testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Humphrey Perimetry
Description: Visual Field Testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Humphrey Perimetry
Description: Visual Field Testing

Intervention type: OTHER
Group type: OTHER
Intervention: Applanation Tonometry
Description: Measurement of Intraocular Pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applanation Tonometry
Description: Measurement of Intraocular Pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applanation Tonometry
Description: Measurement of Intraocular Pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applanation Tonometry
Description: Measurement of Intraocular Pressure
Study: NCT02858102

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity program
Description: The intensity of physical activity will be adapted to the possibilities of the participants making individualized proposals to encourage participants to acquire active lifestyle habits to improve their health. All sessions end with a routine of relaxation and passive stretching. Simultaneously self-employment is controlled outside the guided sessions.
Study: NCT01587274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg twice/ day x 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg twice/ day x 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500mg twice/ day x 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine
Description: Cyclobenzaprine 5-10mg three times/ day x 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/ acetaminophen
Description: Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
Study: NCT01192204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% FBR containing bioadhesive gel
Description: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: 0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
Study: NCT04257604

Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel tablets.
Study: NCT01254266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inpatient treatment with follow up
Description: 1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
Study: NCT01157806

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: short course of palliative radiotherapy
Description: 5x5 Gy + XELOX 7 days after radiotherapy
Study: NCT00755404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD Solution
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD solution containing L-carnitine
Description: Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
Study: NCT03198975

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance image
Description: Histologically-diagnosed primary HCC after curative hepatectomy. The magnetic resonance image will be imported into the software ,and the radiomic textural features will be automatically extracted by the Analysis-Kit software.The high-throughput extracted features will be then selected and a prediction model will be developed in the training set in which patients were collected from a retrospective study. In this project, an independent validation set will be collected and used to validate the prediction accuracy of the model.
Study: NCT00499174

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Radical prostatectomy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: brachytherapy
Description: high dose rate temporary seed implant; permanent seed implant.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy
Description: 3D conformal radiation therapy; intensity modulated radiation therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies
Description: Periodic repeat biopsies